Tuesday, February 5, 2013
BrainStorm Cell Therapeutics Inc., of New York, began treating its first patient in a Phase IIa trial of its stem cell therapy in amyotrophic lateral sclerosis. Three groups of four patients will be treated with intramuscular and intrathecal administration of NurOwn cells, in increasing doses.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.